2 research outputs found
Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease where liver biopsy remains the gold standard for diagnosis. Here we aimed
to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor
1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with
the metabolome.
Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured
by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and
healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD,
31 controls) and correlated with clinical data, histology, genetic parameters, and
serum metabolomics.
Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC
0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between
obese and non-obese healthy controls, suggesting that obesity is not a confounding
factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis
(NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation
cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC
0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay
performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized
ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).
Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with
specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.CR was funded by FEDER through the COMPETE program
and by national funds through Fundação para a Ciência
e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01-
0145-FEDER-029097) and by European Horizon 2020 (H2020-
MSCA-RISE-2016-734719). This work was also supported by
Fundação para a Ciência e Tecnologia (PD/BD/135467/2017)
and Portuguese Association for the Study of Liver/MSD
2017. JB was funded by Spanish Carlos III Health Institute
(ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program
CON14/00129 and CPII19/00008), co-financed by Fondo
Europeo de Desarrollo Regional (FEDER), Instituto de Salud
Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation
(HR17-00601), Fundación Científica de la Asociación Española
Contra el Cáncer, and European Horizon 2020 (ESCALON
project: H2020-SC1-BHC-2018-2020)
Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery
Background: Non-alcoholic fatty liver disease (NAFLD) is caused by abnormal accumulation of lipids within liver cells. Its prevalence is increasing in developed countries in association with obesity, and it represents a risk factor for non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Since NAFLD is usually asymptomatic at diagnosis, new non-invasive approaches are needed to determine the hepatic lipid content in terms of diagnosis, treatment and control of disease progression. Here, we investigated the potential of magnetic resonance imaging (MRI) to quantitate and monitor the hepatic triglyceride concentration in humans.
Methods: A prospective study of diagnostic accuracy was conducted among 129 consecutive adult patients (97 obesity and 32 non-obese) to compare multi-echo MRI fat fraction, grade of steatosis estimated by histopathology, and biochemical measurement of hepatic triglyceride concentration (that is, Folch value).
Results: MRI fat fraction positively correlates with the grade of steatosis estimated on a 0 to 3 scale by histopathology. However, this correlation value was stronger when MRI fat fraction was linked to the Folch value, resulting in a novel equation to predict the hepatic triglyceride concentration (mg of triglycerides/g of liver tissue = 5.082 + (432.104 * multi-echo MRI fat fraction)). Validation of this formula in 31 additional patients (24 obese and 7 controls) resulted in robust correlation between the measured and estimated Folch values. Multivariate analysis showed that none of the variables investigated improves the Folch prediction capacity of the equation. Obese patients show increased steatosis compared to controls using MRI fat fraction and Folch value. Bariatric surgery improved MRI fat fraction values and the Folch value estimated in obese patients one year after surgery.
Conclusions: Multi-echo MRI is an accurate approach to determine the hepatic lipid concentration by using our novel equation, representing an economic non-invasive method to diagnose and monitor steatosis in humans.This research was supported by grants from: the Spanish Ministry of Economy and Competitiveness (J. M. Banales: FIS PI12/00380, R. Jimenez: FIS PI10/01984), the Spanish Carlos III Health Institute (ISCIII) (J. M. Banales, L. Bujanda: Ciberehd), and the Spanish Association Against Cancer (AECC: J. M. Banales, L. Bujanda); the Department of Industry of the Basque Country (J. M. Banales: SAIO12-PE12BN002); the Health Department of the Basque Country (R. Jimenez: Exp 2010111043); the Department of Education, Universities and Research of the Basque Country (M. P. Portillo: IT-572-13), and the University of the Basque Country (M. P. Portillo: UFI 11/32, ELDUNANOTEK). CIBER-ESP, CIBER-obn, and CIBERehd are funded by the Spanish Carlos III Health Institute (ISCIII)